Nordic Myeloma Study Group
Nordic Myeloma Study Group
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 2 | 2026-04-15 | NCT07107529 | |
| Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. | Neoplasms by Histologic Type, neoplasm, plasma cell neoplasm | Active, not recruiting | Phase 2 | 2025-08-08 | NCT03314636 | |
| Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2025-04-03 | NCT03376672 |